78 related articles for article (PubMed ID: 17848662)
1. Gene mutation revelation points to new target for myeloma treatment, studies say.
Garber K
J Natl Cancer Inst; 2007 Sep; 99(18):1362-4. PubMed ID: 17848662
[No Abstract] [Full Text] [Related]
2. Captivating bortezomib: an active but still mysterious drug.
Di Raimondo F; Conticello C
Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
[No Abstract] [Full Text] [Related]
3. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
4. [Molecular pathogenesis of myeloma for the therapeutic targets].
Hanamura I
Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
[TBL] [Abstract][Full Text] [Related]
5. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
6. [Situation of translational research and development of molecular-targeted agents for multiple myeloma].
Kizaki M
Nihon Rinsho; 2007 Dec; 65(12):2357-61. PubMed ID: 18069283
[TBL] [Abstract][Full Text] [Related]
7. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
10. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
11. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
13. 20S ways to apoptosis.
McConkey DJ
Nat Chem Biol; 2008 Sep; 4(9):528-9. PubMed ID: 18711380
[No Abstract] [Full Text] [Related]
14. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Terpos E
Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
[No Abstract] [Full Text] [Related]
15. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
Hongming H; Jian H
Leuk Res; 2009 Jan; 33(1):115-22. PubMed ID: 18778854
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors.
Wilkes G
Oncology (Williston Park); 2007 Apr; 21(4 Suppl):48. PubMed ID: 17508503
[No Abstract] [Full Text] [Related]
19. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
